. 2022 Mar 14;11(14):2855–2864. doi: 10.1002/cam4.4645

TABLE 1.

Comparison of baseline and STMs levels between histological subtypes of LUAD

Characteristics	LPA	APA	PPA	SPA	MPA	p
Characteristics	n = 931	n = 1933	n = 135	n = 80	n = 21	p
Gender = female	580 (62.3%)	1183 (61.2%)	78 (57.8%)	22 (27.5%)	10 (47.6%)	<0.001
Age	58.22 ± 10.46	59.67 ± 10.81	58.01 ± 9.40	61.61 ± 8.98	61.71 ± 7.63	0.001
Tumor size (cm)	1.37 ± 0.62	1.82 ± 0.87	1.84 ± 0.99	2.67 ± 1.24	2.71 ± 1.27	<0.001
Ki‐67	8.00 (5.00–10.00)	10.00 (5.00–25.00)	15.00 (8.00–25.00)	50.00 (30.00–75.00)	30.00 (15.00–50.00)	<0.001
AFP	2.67 (1.90–3.74)	2.78 (1.99–3.97)	3.02 (2.01–4.17)	2.31 (1.78–3.52)	3.09 (2.38–4.36)	0.050
CEA	1.83 (1.25–2.76)	2.09 (1.34–3.23)	2.03 (1.30–3.00)	3.41 (2.42–5.50)	3.24 (2.42–5.69)	<0.001
CA199	10.00 (6.71–15.35)	10.16 (6.70–15.68)	10.52 (7.01–14.67)	11.61 (5.68–21.73)	13.26 (6.05–28.07)	0.580
CA724	1.72 (1.11–3.63)	1.75 (1.07–3.84)	1.93 (1.09–3.82)	2.02 (1.21–5.46)	7.06 (1.63–11.76)	0.059
CYFRA21‐1	1.99 (1.50–2.60)	2.07 (1.58–2.72)	2.01 (1.52–2.61)	2.47 (1.99–3.27)	2.04 (1.60–2.43)	<0.001
NSE	16.92 (14.44–20.32)	16.51 (14.11–19.84)	16.77 (14.13–20.63)	17.67 (14.98–21.87)	16.86 (15.00–21.73)	0.063
AFP_positive(%) ^a	2 (0.2%)	2 (0.1%)	0 (0.0)	0 (0.0)	1 (4.8%)	<0.001
CEA_ positive(%) ^a	54 (5.8%)	246 (12.7%)	16 (11.9%)	27 (33.8%)	7 (33.3%)	<0.001
CA199_positive(%) ^a	13 (1.4%)	32 (1.7%)	3 (2.2%)	6 (7.5%)	1 (4.8%)	0.002
CA724_positive(%) ^a	95 (10.2%)	206 (10.7%)	17 (12.6%)	10 (12.7%)	9 (42.9%)	<0.001
CYFRA21‐1_positive(%) ^a	92 (9.9%)	262 (13.6%)	18 (13.3%)	19 (24.1%)	2 (9.5%)	0.002
NSE_positive(%) ^a	526 (56.5%)	1008 (52.2%)	69 (51.1%)	44 (55.7%)	12 (57.1%)	0.263

Abbreviations: APA, acinar‐predominant adenocarcinoma; LPA, lepidic‐predominant adenocarcinoma; MPA, micropapillary‐predominant adenocarcinoma; PPA, papillary‐predominant adenocarcinoma; SPA, solid‐predominant adenocarcinoma.

^{^a}

Patients with abnormal levels of STMs.

P value of <0.05 was marked in bold.